Abstract: A children's or infant's nutritional product utilizing or containing one or more inactivated probiotics for preventing or reducing systemic and/or respiratory inflammation in a child or infant.

Abstract: The present disclosure is directed to a novel nutritional formula for treating or preventing systemic inflammation in a subject. The nutritional formula comprises a therapeutically effective amount of inactivated Lactobacillus rhamnosus GG (LGG).

Abstract: A method for identifying allergenic proteins and peptides. More specifically, a method for identifying allergenic milk proteins and/or peptides including the steps of: providing at least one expression library comprising DNA or cDNA derived from the mammary gland tissue of a lactating cow, expressing at least one protein or peptide encoded by said expression library, determining the binding capacity of said at least one protein or peptide to IgE of at least one serum of an individual who is sensitive to cow's milk, contacting the at least one protein or peptide exhibiting an IgE binding capacity as determined in step c) with basophil cells, eosinophil cells or mast cells and identifying the at least one protein or peptide as being allergenic when said basophil cells, eosinophil cells or mast cells release upon contact with at least one protein or peptide of step d) at least one mediator.

Abstract: A process for the preparation of a non-viable probiotic composition having anti-allergic (i.e. allergy preventive and/or anti-allergic in a therapeutic sense) properties, the process including the steps of (a) subjecting LGG to cultivation in a suitable culture medium using a batch process; (b) harvesting the culture supernatant at a late exponential phase of the cultivation step; (c) removing liquid contents from the culture supernatant so as to obtain the composition. Also, a composition comprising a proteinaceous mixture, said composition being obtainable by the above process, and the use thereof in a dietetic product preferably for targeting expecting mother's, infants, or children as well as application in food for specific medical purposes.

Abstract: A nutritional formulation or supplement comprising a cow's milk peptide-containing hydrolysate and/or peptide-containing fraction of the hydrolysate and/or one or more peptides derived from a protein present in cow's milk for use in the induction of tolerance in a human subject, wherein said peptides contained in the hydrolysate or fraction of hydrolysate comprise T cell epitope-containing peptides or wherein said one or more peptides are T cell epitope-containing peptides, and wherein said T cell epitope-containing peptides are capable of driving the immune reaction upon intake of the nutritional formulation towards tolerance.

Abstract: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.

Abstract: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.

Abstract: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.

Abstract: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.

Abstract: A method for identifying allergenic proteins and peptides. More specifically, a method for identifying allergenic milk proteins and/or peptides including the steps of: providing at least one expression library comprising DNA or cDNA derived from the mammary gland tissue of a lactating cow, expressing at least one protein or peptide encoded by said expression library, determining the binding capacity of said at least one protein or peptide to IgE of at least one serum of an individual who is sensitive to cow's milk, contacting the at least one protein or peptide exhibiting an IgE binding capacity as determined in step c) with basophil cells, eosinophil cells or mast cells and identifying the at least one protein or peptide as being allergenic when said basophil cells, eosinophil cells or mast cells release upon contact with at least one protein or peptide of step d) at least one mediator.

Abstract: The present invention is directed to a novel method for treating or preventing systemic inflammation in a subject. The method administering to the subject a therapeutically effective amount of inactivated LGG.

Abstract: A novel method and product utilizing or containing one or more inactivated probiotics.

Abstract: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.

Abstract: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.

Abstract: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.

Abstract: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.

Abstract: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.

Abstract: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.

Abstract: The present invention is directed to a novel method for treating or preventing systemic inflammation in a formula-fed infant. The method administering to the infant a therapeutically effective amount of LGG in combination with at least one LCPUFA.

Abstract: The present invention is directed to a novel method for treating or preventing systemic inflammation in a formula-fed infant. The method administering to the infant a therapeutically effective amount of LGG in combination with at least one LCPUFA.